3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
1
Phase 4
1
Phase 3
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
79
Triple Negative Breast Neoplasms
9
Stomach Neoplasms
8
Inflammatory Breast Neoplasms
6
Carcinoma, Hepatocellular
6
Non-Muscle Invasive Bladder Neoplasms
3
Esophageal Neoplasms
3
Sarcoma
2
Primary Breast Cancer
2
Pathologic Complete Response
2
Lung Neoplasms
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma
1
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oesophago-gastric Cancer
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Malignant mesenchymal tumor
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Interventions
Rituximab
66
Cyclophosphamide
46
Vincristine
40
Doxorubicin
40
Prednisone
35
Etoposide
19
Radiotherapy
14
Gemcitabine
13
Peripheral Blood Stem Cell Transplantation
12
Filgrastim
12
Cytarabine
12
Lenalidomide
11
Carmustine
10
VAP-cyclo protocol
9
Prednisolone
9
Oxaliplatin
9
Melphalan
9
Methotrexate
7
Ifosfamide
7
Mitoxantrone
6
Bleomycin
6
polatuzumab vedotin
5
R-CHOP protocol
4
Methylprednisolone
4
Injections
4
Granulocyte Colony-Stimulating Factor
4
Cyclosporine
4
Cisplatin
4
Carboplatin
4
pegfilgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Large B-Cell, Diffuse
×
Epirubicin
×
Clear all
NCT01148446
2010-06-22
ANZINTER3
Fondazione Italiana Linfomi - ETS
Phase 3
Completed
226 enrolled